Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Veracyte Inc
(NQ:
VCYT
)
25.56
+2.97 (+13.15%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 19, 2022
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.
Via
Benzinga
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
October 18, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
October 13, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
September 22, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
September 13, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
September 11, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
September 07, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
September 01, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
August 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
August 29, 2022
From
Veracyte, Inc.
Via
Business Wire
Whither Small Caps After Fed’s Tough Talk?
August 29, 2022
For now its better not to “Fight the Fed” because they are fighting the with the market. Now that everyone is scared of the Fed's rhetoric it would be better to wait a week or so as more data and...
Via
Talk Markets
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
August 11, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte: Q2 Earnings Insights
August 02, 2022
Veracyte (NASDAQ:VCYT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Veracyte beat estimated earnings by...
Via
Benzinga
Veracyte Announces Second Quarter 2022 Financial Results
August 02, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte's Earnings: A Preview
August 01, 2022
Veracyte (NASDAQ:VCYT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Veracyte will...
Via
Benzinga
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
July 20, 2022
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For August 2, 2022
August 02, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Via
Benzinga
Small Cap Biotech Stocks Are Trending Well
July 18, 2022
Despite a little weakness last week, small cap biotechs are trending well for traders. For investors entering the trade on July 5 all of our. focus stocks are up except ChemoCentryx.
Via
Talk Markets
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
July 14, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
July 13, 2022
From
Veracyte, Inc.
Via
Business Wire
Small Cap Biotechs Regain Momentum
July 11, 2022
Smaller cap biotech stocks soared off from recent lows looking like a redux of early 2021 when prices were double that of current values.
Via
Talk Markets
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
June 27, 2022
From
Veracyte, Inc.
Via
Business Wire
Bear Market Rally Lifts HealthCare Stocks Off Bottom
June 22, 2022
Clearly we are in a biotech bear market with both diagnostics and vaccine revenues stalled. If gene editing stocks cannot offer breakthrough clinical news then stick with large cap biopharma.
Via
Talk Markets
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
June 20, 2022
From
Veracyte, Inc.
Via
Business Wire
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
June 03, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
May 31, 2022
From
Veracyte, Inc.
Via
Business Wire
New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Present at Upcoming Investor Conferences
May 26, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
May 16, 2022
From
Veracyte, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.